Background: Neoadjuvant anti-programmed cell death 1 (PD-1) immunochemotherapy has shown promising efficiency in the treatment of early-stage non-small-cell lung cancer (NSCLC), but it has not consistently yielded durable responses. Biomarkers for the prediction of efficacy are warranted.
Methods: We performed shotgun metagenomic and plasma/faecal metabolomic studies in 44 NSCLC patients who underwent neoadjuvant tislelizumab plus platinum-based doublet chemotherapy. Samples were collected at baseline and before surgical resection, and the major pathologic response (MPR) was evaluated.
Results: MPR patients showed a significantly higher gut-microbial alpha diversity, an enrichment of Ruminococcaceae, Lachnospiraceae and Clostridiales species, and an increased plasma level of tryptophan metabolites at baseline. On the contrary, non-MPR patients were characterized by enrichment of Prevotella species in faecal samples and higher plasma levels of linoleic acid metabolites. A high predictive accuracy was achieved using a small panel of differential microbial (Clostridium sp. M62/1 and Eisenbergiella tayi) or metabolomic features (linoleic acid, oxindole-3-acetic acid and quinolinic acid) with AUCs > .85.
Conclusions: The baseline characteristics of the gut microbiota and plasma metabolites could provide early predictions of the response to neoadjuvant anti-PD-1 immunochemotherapy.
Trial registration: NCT05244837.
| [1] |
Zhou Y, Li A, Yu H, et al. Neoadjuvant-adjuvant vs neoadjuvant-only PD-1 and PD-L1 inhibitors for patients with resectable NSCLC: an indirect meta-analysis. JAMA Netw Open. 2024; 7(3):e241285.
|
| [2] |
Yue D, Wang W, Liu H, et al. Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial. Lancet Respir Med. 2025; 13(2): 119-129.
|
| [3] |
Lu S, Zhang W, Wu L, Wang W, Zhang P, Fang W, et al. Perioperative toripalimab plus chemotherapy for patients with resectable non-small cell lung cancer: the neotorch randomized clinical trial. JAMA. 2024; 331(3): 201-211.
|
| [4] |
Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. New Eng J Med. 2018; 378(21): 1976-1986.
|
| [5] |
Shu CA, Gainor JF, Awad MM, et al. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020; 21(6): 786-795.
|
| [6] |
Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 2016; 17(12): e542-e51.
|
| [7] |
Derosa L, Routy B, Thomas AM, et al. Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. Nat Med. 2022; 28(2): 315-324.
|
| [8] |
Jin Y, Dong H, Xia L, et al. The diversity of gut microbiome is associated with favorable responses to anti-programmed death 1 immunotherapy in Chinese patients with NSCLC. J Thorac Oncol. 2019; 14(8): 1378-1389.
|
| [9] |
Derosa L, Iebba V, Silva CAC, et al. Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome. Cell. 2024; 187(13): 3373-3389.
|
| [10] |
Nie X, Xia L, Gao F, et al. Serum metabolite biomarkers predictive of response to PD-1 blockade therapy in non-small cell lung cancer. Front Mol Biosci. 2021; 8:678753.
|
| [11] |
Lee S-H, Kim S, Lee J, et al. Comprehensive metabolomic analysis identifies key biomarkers and modulators of immunotherapy response in NSCLC patients. Drug Resist Updat. 2024; 77:101159.
|
| [12] |
Zheng L, Hu F, Huang L, et al. Association of metabolomics with PD-1 inhibitor plus chemotherapy outcomes in patients with advanced non-small-cell lung cancer. J Immunother Cancer. 2024; 12(4):e008190.
|
| [13] |
Agus A, Clément K, Sokol H. Gut microbiota-derived metabolites as central regulators in metabolic disorders. Gut. 2021; 70(6): 1174-1182.
|
| [14] |
Deja S, Porebska I, Kowal A, et al. Metabolomics provide new insights on lung cancer staging and discrimination from chronic obstructive pulmonary disease. J Pharm Biomed Anal. 2014; 100: 369-380.
|
| [15] |
Tetzlaff MT, Messina JL, Stein JE, et al. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Ann Oncol. 2018; 29(8): 1861-1868.
|
| [16] |
Tsugawa H, Cajka T, Kind T, et al. MS-DIAL: data-independent MS/MS deconvolution for comprehensive metabolome analysis. Nat Methods. 2015; 12(6): 523-526.
|
| [17] |
Fan S, Kind T, Cajka T, et al. Systematic error removal using random forest for normalizing large-scale untargeted lipidomics data. Anal Chem. 2019; 91(5): 3590-3596.
|
| [18] |
Dixon P. VEGAN, a package of R functions for community ecology. J Vegetat Sci. 2003; 14(6): 927-930.
|
| [19] |
Gloor GB, Wu JR, Pawlowsky-Glahn V, Egozcue JJ. It's all relative: analyzing microbiome data as compositions. Ann Epidemiol. 2016; 26(5): 322-329.
|
| [20] |
Tsilimigras MCB, Fodor AA. Compositional data analysis of the microbiome: fundamentals, tools, and challenges. Ann Epidemiol. 2016; 26(5): 330-335.
|
| [21] |
Templ M, Hron Karel, Filzmoser Peter. robCompositions: an R-package for robust statistical analysis of compositional data. Composition Data Anal Theory Appl. 2011: 341-355.
|
| [22] |
Mallick H, Rahnavard A, McIver LJ, et al. Multivariable association discovery in population-scale meta-omics studies. PLoS Comput Biol. 2021; 17(11):e1009442.
|
| [23] |
Nixon MP, Letourneau J, David L, Mukherjee S, Silverman JD, A Statistical Analysis of Compositional Surveys. 2022.
|
| [24] |
Nearing JT, Douglas GM, Hayes MG, et al. Microbiome differential abundance methods produce different results across 38 datasets. Nat Commun. 2022; 13(1): 342.
|
| [25] |
Ghazi AR, Sucipto K, Rahnavard A, et al. High-sensitivity pattern discovery in large, paired multiomic datasets. Bioinformatics. 2022; 38(Suppl 1): i378-i85.
|
| [26] |
Gao S, Li N, Gao S, Xue Q, et al. Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC. J Thorac Oncol. 2020; 15(5): 816-826.
|
| [27] |
Capone M, Giannarelli D, Mallardo D, et al. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. J Immunother Cancer. 2018; 6(1): 74.
|
| [28] |
Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018; 359(6371): 91-97.
|
| [29] |
Newsome RC, Gharaibeh RZ, Pierce CM, et al. Interaction of bacterial genera associated with therapeutic response to immune checkpoint PD-1 blockade in a United States cohort. Genome Med. 2022; 14(1): 35.
|
| [30] |
Elsden SR, Hilton MG, Waller JM. The end products of the metabolism of aromatic amino acids by Clostridia. Arch Microbiol. 1976; 107(3): 283-288.
|
| [31] |
Peng Z, Cheng S, Kou Y, et al. The gut microbiome is associated with clinical response to anti-PD-1/PD-L1 immunotherapy in gastrointestinal cancer. Cancer Immunol Res. 2020; 8(10): 1251-1261.
|
| [32] |
Wang K, Kim MK, Di Caro G, et al. Interleukin-17 receptor a signaling in transformed enterocytes promotes early colorectal tumorigenesis. Immunity. 2014; 41(6): 1052-1063.
|
| [33] |
Hill M, Segovia M, Russo S, Girotti MR, Rabinovich GA. The paradoxical roles of inflammation during PD-1 blockade in cancer. Trends Immunol. 2020; 41(11): 982-993.
|
| [34] |
Braun DA, Street K, Burke KP, et al. Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. Cancer Cell. 2021; 39(5): 632-648.
|
| [35] |
Saini RK, Keum Y-S. Omega-3 and omega-6 polyunsaturated fatty acids: dietary sources, metabolism, and significance—A review. Life Sci. 2018; 203: 255-267.
|
| [36] |
Sriram K. Confusion between gamma-linolenic acid and gamma-linoleic acid. Crit Care Med. 2011; 39(12): 2789. author reply -; author reply 90.
|
| [37] |
Edin ML, Duval C, Zhang G, Zeldin DC. Role of linoleic acid-derived oxylipins in cancer. Cancer Metastasis Rev. 2020; 39(3): 581-582.
|
| [38] |
Kawasaki H, Chang HW, Tseng HC, et al. A tryptophan metabolite, kynurenine, promotes mast cell activation through aryl hydrocarbon receptor. Allergy. 2014; 69(4): 445-452.
|
| [39] |
Qiao P, Zhang C, Yu J, et al. Quinolinic acid, a tryptophan metabolite of the skin microbiota, negatively regulates NLRP3 inflammasome through AhR in psoriasis. J Invest Dermatol. 2022; 142(8).
|
| [40] |
Li M, Ding Y, Wei J, et al. Gut microbiota metabolite indole-3-acetic acid maintains intestinal epithelial homeostasis through mucin sulfation. Gut Microbes. 2024; 16(1):2377576.
|
| [41] |
Russell WR, Duncan SH, Scobbie L, et al. Major phenylpropanoid-derived metabolites in the human gut can arise from microbial fermentation of protein. Mol Nutr Food Res. 2013; 57(3): 523-535.
|
| [42] |
Tintelnot J, Xu Y, Lesker TR, et al. Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer. Nature. 2023; 615(7950): 168-174.
|
| [43] |
Niwa T, Ishii S, Hiramatsu A, Osawa T. Oxidative reaction of oxindole-3-acetic acids. Biosci Biotechnol Biochem. 2003; 67(9): 1870-1874.
|
| [44] |
Sadauskas M, Statkevičiūtė R, Vaitekūnas J, Meškys R. Bioconversion of biologically active indole derivatives with indole-3-acetic acid-degrading enzymes from Caballeronia glathei DSM50014. Biomolecules. 2020; 10(4).
|
| [45] |
Sahm F, Oezen I, Opitz CA, et al. The endogenous tryptophan metabolite and NAD+ precursor quinolinic acid confers resistance of gliomas to oxidative stress. Cancer Research. 2013; 73(11): 3225-3234.
|
| [46] |
Kesarwani P, Kant S, Zhao Y, et al. Quinolinate promotes macrophage-induced immune tolerance in glioblastoma through the NMDAR/PPARγ signaling axis. Nat Commun. 2023; 14(1): 1459.
|
| [47] |
Wang Y, Song W, Wang J, et al. Single-cell transcriptome analysis reveals differential nutrient absorption functions in human intestine. J Exp Med. 2020; 217(2):e20191130.
|
RIGHTS & PERMISSIONS
2026 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.
PDF
